CROI 2024 TB research round up
Treatment Action Group (TAG) released an overview of TB research data reported at the 31st Conference on Retroviruses and Opportunistic Infections (CROI 2024) held on 3-6 March 2024 in Denver, Colorado, USA.
The highlights cover the results of several phase II TB prevention and treatment trials:
- DOLPHIN TOO (NCT03435146) determined that people can safely start HIV treatment with dolutegravir and the TB preventive treatment regimen known as 3HP on the same day.
- The H56:IC31 TB vaccine candidate (NCT03512249) did not prevent recurrent TB, defined as either relapse or reinfection, among people who recently finished drug-sensitive TB treatment.
- Quabodepistat, a new TB drug with a novel mechanism of action, given in combination with delamanid and bedaquiline (NCT05221502) appears to be safe and effective against drug-sensitive TB based on outcomes measured at the end of treatment.
- A three-month clofazimine- and rifapentine-containing regimen (NCT04311502) lacked clinical efficacy compared to the six-month standard of care for drug-sensitive TB (HRZE) -- the trial was stopped early by an independent safety data monitoring board.
- A reproductive safety study (NCT04179500) that measured changes from baseline in total sperm count, sperm concentration, sperm volume, and male reproductive hormones found that pretomanid does not have negative effects on the reproductive function of adult males.
More in depth summaries of these findings and TAG’s accompanying analyses are available here.
Source: TAG
